Categories Earnings

Verizon’s Q3 results beat expectations

Verizon Communications Inc. (NYSE: VZ) topped revenue and earnings estimates for the third quarter of 2019, allowing shares to climb over 1% in premarket hours on Friday.

Consolidated revenues of $32.9 billion were up 0.9% from the same period last year and ahead of the consensus estimate of $32.7 billion. Revenue growth was driven mainly by higher wireless service revenues.  

Verizon beat Q3 revenue and earnings estimates

GAAP net income grew 5% year-over-year to $5.3 billion, or $1.25 per share. Adjusted EPS was $1.25, above forecasts of $1.24.  

Wireless revenues, on an adjusted basis, grew 2.6% year-over-year to $23.6 billion while wireline revenues dropped 3.8% to $7.1 billion.  

Consumer segment revenues grew 1.4% year-over-year to $22.7 billion, driven by growth in wireless service revenue and Fios service offerings. Wireless retail postpaid net additions totaled 193,000 during the quarter. Phone net additions more than doubled year-over-year to 239,000.

The company saw a growth in postpaid smartphone net additions, driven by a 10% increase in phone gross additions. Consumer wireless service revenues rose 2.1%, driven by customer step-ups to higher-priced plans and an increase in connections per account. Total retail postpaid churn was 1.05%.   

Also read: Verizon Q3 2019 Earnings Preview

In the Business segment, revenues remained flat year-over-year at $7.9 billion, as growth in wireless revenue was offset by declines in wireline products. Wireless retail postpaid net additions rose 12.1% to 408,000. Retail postpaid churn was 1.22%.

Media revenues dropped 2% to $1.8 billion versus the prior-year period, as gains in mobile advertising were offset by declines in desktop advertising.

For the full year of 2019, Verizon expects a low single-digit percentage growth in both adjusted EPS and GAAP consolidated revenues.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top